Cogent Biosciences (COGT) Net Income towards Common Stockholders: 2017-2020
Historic Net Income towards Common Stockholders for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to -$11.4 million.
- Cogent Biosciences' Net Income towards Common Stockholders fell 595.65% to -$11.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.1 million, marking a year-over-year decrease of 157.77%. This contributed to the annual value of -$82.1 million for FY2020, which is 157.77% down from last year.
- Per Cogent Biosciences' latest filing, its Net Income towards Common Stockholders stood at -$11.4 million for Q4 2020, which was up 80.09% from -$57.2 million recorded in Q3 2020.
- Over the past 5 years, Cogent Biosciences' Net Income towards Common Stockholders peaked at $2.3 million during Q4 2019, and registered a low of -$57.2 million during Q3 2020.
- For the 3-year period, Cogent Biosciences' Net Income towards Common Stockholders averaged around -$12.4 million, with its median value being -$9.6 million (2018).
- In the last 5 years, Cogent Biosciences' Net Income towards Common Stockholders surged by 126.69% in 2019 and then tumbled by 595.65% in 2020.
- Cogent Biosciences' Net Income towards Common Stockholders (Quarterly) stood at -$6.7 million in 2017, then fell by 28.33% to -$8.6 million in 2018, then soared by 126.69% to $2.3 million in 2019, then tumbled by 595.65% to -$11.4 million in 2020.
- Its last three reported values are -$11.4 million in Q4 2020, -$57.2 million for Q3 2020, and -$7.4 million during Q2 2020.